<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The aim of the present study was to evaluate the effect of <z:chebi fb="0" ids="8871">risperidone</z:chebi> in patients afflicted by <z:e sem="disease" ids="C0004352" disease_type="Mental or Behavioral Dysfunction" abbrv="">autistic disorder</z:e> especially with regards to its three core symptoms, including "relating to others", "communication skills", and "<z:hpo ids='HP_0000733'>stereotyped behaviors</z:hpo>" based on Childhood <z:hpo ids='HP_0000717'>Autism</z:hpo> Rating Scale (CARS) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: An 8-week open-label study of <z:chebi fb="0" ids="8871">risperidone</z:chebi> for treatment of <z:e sem="disease" ids="C0004352" disease_type="Mental or Behavioral Dysfunction" abbrv="">autistic disorder</z:e> in children 4-17 years old was designed </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="8871">Risperidone</z:chebi> dose titration was as follow: 0.02 mg/kg/day at the first week, 0.04 mg/kg/day at the second week, and 0.06 mg/kg/day at the third week and thereafter </plain></SENT>
<SENT sid="3" pm="."><plain>The outcome measures were scores obtained by CARS, Aberrant Behavior Checklist (ABC), and Clinical Global Impression-Improvement (CGI-I) scale </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Fifteen patients completed this study </plain></SENT>
<SENT sid="5" pm="."><plain>After 8 weeks, CARS total score decreased significantly, (P=0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>At the end of the study, social interactions and verbal communication skills of the patients were significantly improved (P&lt;0.001, P=0.03, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>However, <z:hpo ids='HP_0000733'>stereotypic behaviors</z:hpo> did not show any significant change in this study </plain></SENT>
<SENT sid="8" pm="."><plain>Increase in appetite and <z:hpo ids='HP_0001262'>somnolence</z:hpo> were the most reported side effects </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: This study suggests that <z:chebi fb="0" ids="8871">risperidone</z:chebi> may be an effective treatment for the management of core symptoms of <z:e sem="disease" ids="C0004352" disease_type="Mental or Behavioral Dysfunction" abbrv="">autistic disorder</z:e> </plain></SENT>
</text></document>